A new syndicate, Peers Capital, launches to fund preventive health at the earliest stage
The investor group is backing pre-seed and seed founders across diagnostics, recovery, and longevity through a deal-by-deal model — and they have already closed its first investments
media age.house
A new investment syndicate focused on preventive health, Peers Capital, has launched to back founders at the earliest stages of building, the firm announced this week.
The syndicate targets pre-seed and seed companies across five areas — diagnostics, recovery, longevity, behaviour change, and what it calls “the infrastructure making prevention scalable.” It is led by four operators whose backgrounds span the venture studios and operating companies Peers Studio, Foundrise, and UNTIL.
Who Is Behind It
The four founders are Daniel Chappell, Agata Andryszczak, Nick Gnan, and Keno Peer. Between them, they have:
- Made more than a dozen sweat-equity and angel investments;
- Supported over $40 million in capital raised across partner companies; and
- Worked with founders from pre-seed through Series A.
Companies they have worked alongside include Everyday Dose, The Protocole, The Blood, Baseline, Youth, Extension Health, Monk Icebath, and Spoon Granola.
How the Model Works
Peers Capital is structured as a syndicate rather than a fund. Instead of committing to a blind pool, members opt into individual opportunities and review each one before deciding whether to participate.
| Detail | Figure |
|---|---|
| Typical investment per company | €75,000 – €500,000 |
| Annual commitment to join | from €50,000 |
| Individual deal participation | from €5,000 |
| Investment vehicle | UK-based, tax-transparent SPVs |
| Geographies | US, EU, and the GCC |
Beyond capital, the syndicate pitches founders on strategic support, industry connections, and access to operators who have built businesses across health, wellness, and consumer products. The firm says it has already closed its first deals.
Where It Sits in the Market
The launch lands at a moment when capital is increasingly flowing toward the consumer-facing edge of longevity — diagnostics, recovery products, and behaviour-change tools that reach customers earlier than traditional healthcare. Peers Capital frames preventive health as still being “in its infancy,” arguing that the larger shift comes when prevention is treated as the foundation of healthcare rather than an add-on to it.
The model is deliberately deal-by-deal: no blind pool, no fund commitment, and full visibility into each opportunity before money moves.
That positioning places the syndicate squarely in the prevention-and-wellness layer of the longevity market rather than the basic-science layer pursued by cellular-reprogramming and aging-biology companies. It is a layer that maps closely to venture’s near-term return horizon — consumer health products and diagnostics can show commercial signal far faster than therapeutics targeting the biology of aging.
Disclaimer
This content is for informational and educational purposes only and is not medical advice. Always consult a qualified healthcare professional before making changes to your health.
